natgillin/translations-raw huggingface dataset:
In a study comparing 1 dose (N=1114) to 2 doses (N=1102) of Varicella Vaccine live (Oka/Merck), the estimated vaccine efficacy against all severities of varicella disease for the 10-year observation period was 94% for 1 dose and 98% for 2 doses (p &lt; 0.001).
U ispitivanju u kojem se uspoređivala 1 doza (N=1114) do 2 doze (N=1102) živog cjepiva protiv varičele (Oka/Merck), procijenjena djelotvornost cjepiva protiv svih težina varičele tijekom desetgodišnjeg razdoblja promatranja bila je 94% za 1 dozu i 98% za 2 doze (p &lt; 0,001).
In a study conducted in patients with end stage renal disease (ESRD) receiving haemodialysis, dialysis clearance of aliskiren was low ( &lt; 2% of oral clearance).
U ispitivanju provedenom na bolesnicima u završnom stadiju bubrežne bolesti (ESRD) na hemodijalizi klirens aliskirena dijalizom bio je nizak ( &lt; 2% peroralnog klirensa).
In a study conducted in patients with end stage renal disease (ESRD) receiving haemodialysis, dialysis clearance of aliskiren was low ( &lt; 2% of oral clearance).
U ispitivanju provedenom na bolesnicima u završnom stadiju bubrežne bolesti (ESRD) na hemodijalizi klirens aliskirena dijalizom bio bi nizak ( &lt; 2% peroralnog klirensa).
In a study in elderly men and women including 4 patients &gt; 75 years of age, AUC was about 30 and 50% increased compared to young men, respectively.
U ispitivanju sa starijim muškarcima i ženama, uključujući 4 bolesnika starija od 75 godina života, AUC je bio veći za oko 30, odnosno 50% nego kod mladih muškaraca.
In a study in subjects with stable atherosclerosis, the mean AUC of the active metabolite in patients &lt; 60 kg taking 5 mg prasugrel was 38% lower than in patients ≥60 kg taking 10 mg prasugrel, and the antiplatelet effect of 5 mg was similar to 10 mg.
U ispitivanju u kojem su sudjelovali ispitanici sa stabilnom aterosklerozom, srednja vrijednost AUC-a aktivnog metabolita u bolesnika tjelesne težine &lt; 60 kg koji su uzimali prasugrel u dozi od 5 mg bila je 38% niža nego u bolesnika tjelesne težine ≥ 60 kg koji su uzimali prasugrel u dozi od 10 mg, dok je antitrombocitni učinak doze od 5 mg bio podjednak učinku doze od 10 mg.
In a study in subjects with stable atherosclerosis, the mean AUC of the active metabolite in patients ≥75 years old taking 5 mg prasugrel was approximately half that in patients &lt; 65 years old taking 10 mg prasugrel, and the antiplatelet effect of 5 mg was reduced but was non-inferior compared to 10 mg.
U ispitivanju u kojem su sudjelovali ispitanici sa stabilnom aterosklerozom, srednja vrijednost AUC-a aktivnog metabolita u bolesnika u dobi od ≥ 75 godina liječenih prasugrelom u dozi od 5 mg bila je približno dvostruko manja nego u bolesnika mlađih od 65 godina liječenih prasugrelom u dozi od 10 mg, dok je antitrombocitni učinak doze od 5 mg bio manji, ali ne i inferioran u odnosu na dozu od 10 mg.
In a study of 47 young ( &lt; 40 years) healthy volunteers, presumed to be free of β-amyloid, all Amyvid PET scans were negative.
U ispitivanju 47 mladih ( &lt; 40 godina) zdravih dobrovoljaca za koje se pretpostavilo da nemaju β-amiloide, nalazi svih PET oslikavanja uz Amyvid bili su negativni.
In a study of 7,705 postmenopausal women with a mean age of 66 years and with osteoporosis or osteoporosis with an existing fracture, Evista treatment for 3 years reduced the incidence of vertebral fractures by 47 % (RR 0.53, CI 0.35, 0.79; p &lt; 0.001) and 31 % (RR 0.69, CI 0.56, 0.86; p &lt; 0.001) respectively.
U ispitivanju provedenom na 7705 žena u postmenopauzi srednje dobi od 66 godina s osteoporozom ili osteoporozom s postojećim prijelomom, 3-godišnje liječenje Evistom smanjilo je incidenciju prijeloma kralježaka za 47 % (RR 0,53; CI 0,35; 0,79; p &lt; 0,001) odnosno za 31 % (RR 0,69; CI 0,56; 0,86; p &lt; 0,001).
In a study of 7,705 postmenopausal women with a mean age of 66 years and with osteoporosis or osteoporosis with an existing fracture, Optruma treatment for 3 years reduced the incidence of vertebral fractures by 47 % (RR 0.53, CI 0.35, 0.79; p &lt; 0.001) and 31 % (RR 0.69, CI 0.56, 0.86; p &lt; 0.001) respectively.
U ispitivanju provedenom na 7705 žena u postmenopauzi srednje dobi od 66 godina s osteoporozom ili osteoporozom s postojećim prijelomom, 3-godišnje liječenje Optrumom smanjilo je incidenciju prijeloma kralježaka za 47 % (RR 0,53; CI 0,35; 0,79; p &lt; 0,001) odnosno za 31 % (RR 0,69; CI 0,56; 0,86; p &lt; 0,001).
In a study of 7,705 postmenopausal women with a mean age of 66 years and with osteoporosis or osteoporosis with an existing fracture, raloxifene treatment for 3 years reduced the incidence of vertebral fractures by 47 % (RR 0.53, CI 0.35, 0.79; p &lt; 0.001) and 31 % (RR 0.69, CI 0.56, 0.86; p &lt; 0.001) respectively.
U ispitivanju provedenom na 7705 žena u postmenopauzi srednje dobi od 66 godina s osteoporozom ili osteoporozom s postojećim prijelomom, trogodišnje liječenje raloksifenom smanjilo je incidenciju prijeloma kralježaka za 47 % (RR 0,53; CI 0,35; 0,79; p &lt; 0,001), odnosno za 31 % (RR 0,69; CI 0,56; 0,86; p &lt; 0,001).
In a study of adult patients undergoing pharmacological stress radionuclide MPI with Rapiscan, randomized to placebo (n=66) or caffeine (200 mg, n=70 or 400 mg, n=71) administered 90 minutes before the test, caffeine compromised the diagnostic accuracy of detecting reversible perfusion defects (p &lt; 0.001).
U ispitivanju na odraslim bolesnicima koji će se podvrgnuti farmakološkom stresu primjenom Rapiscana radi MPI pomoću radionuklida, u kojem su ispitanici randomizirani u skupinu koja prima placebo (n=66) ili skupinu koja prima kofein (200 mg, n=70 ili 400 mg, n=71) 90 minuta prije testiranja, kofein je kompromitirao dijagnostičku preciznost utvrđivanja reverzibilnih defekata perfuzije (p &lt; 0,001).
In a study of platinum-resistant recurrent ovarian cancer patients, alopecia, mucosal inflammation, peripheral sensory neuropathy, proteinuria and hypertension were also reported and occurred at a rate at least 5% higher in the CTBV arm for bevacizumab-treated patients  65 years of age compared with bevacizumab-treated patients aged &lt; 65 years.
U ispitivanju recidiva karcinoma jajnika rezistentnog na platinu prijavljene su i alopecija, upala sluznice, periferna senzorna neuropatija, proteinurija i hipertenzija, a stopa njihova pojavljivanja u skupini koja je primala kemoterapiju i bevacizumab bila je najmanje 5% veća u bolesnica liječenih bevacizumabom u dobi od ≥ 65 godina nego u bolesnica liječenih bevacizumabom u dobi od ≤ 65 godina.
In a study of the haemodynamic effects of a single oral 100 mg dose of sildenafil in 14 patients with severe coronary artery disease (CAD) ( &gt; 70% stenosis of at least one coronary artery), the mean resting systolic and diastolic blood pressures decreased by 7% and 6% respectively compared to baseline.
U ispitivanju hemodinamičkih učinaka jednokratne oralne doze sildenafila od 100 mg u 14 bolesnika s teškom bolesti koronarnih arterija ( &gt; 70% stenoza barem jedne koronarne arterije), srednji sistolički i dijastolički krvni tlak u mirovanju je snižen za 7%, odnosno 6% u usporedbi s početnom vrijednosti.
In a study of the hemodynamic effects of a single oral 100 mg dose of sildenafil in 14 patients with severe coronary artery disease (CAD) ( &gt; 70 % stenosis of at least one coronary artery), the mean resting systolic and diastolic blood pressures decreased by 7 % and 6 % respectively compared to baseline.
U ispitivanju hemodinamičkih učinaka jedne peroralne doze od 100 mg sildenafila u 14 bolesnika s teškom bolešću koronarnih arterija (stenoza &gt; 70% u barem jednoj koronarnoj arteriji), srednja vrijednost sistoličkog krvnog tlaka u mirovanju snižen je za 7%, a dijastoličkog za 6% u odnosu na početne vrijednosti.
In a study of the hemodynamic effects of a single oral 100 mg dose of sildenafil in 14 patients with severe coronary artery disease (CAD) ( &gt; 70 % stenosis of at least one coronary artery), the mean resting systolic and diastolic blood pressures decreased by 7 % and 6 % respectively compared to baseline.
U ispitivanju hemodinamičkih učinaka jedne peroralne doze od 100 mg sildenafila u 14 bolesnika s teškom bolešću koronarnih arterija (stenoza &gt; 70% u barem jednoj koronarnoj arteriji), srednja vrijednost sistoličkog krvnog tlaka u mirovanju snižena je za 7%, a dijastoličkog za 6% u odnosu na početne vrijednosti.
In a study of the hemodynamic effects of a single oral 100 mg dose of sildenafil in 14 patients with severe coronary artery disease (CAD) ( &gt; 70 % stenosis of at least one coronary artery), the mean resting systolic and diastolic blood pressures decreased by 7 % and 6 % respectively compared to baseline.
U ispitivanju hemodinamičkih učinaka jednokratne oralne doze sildenafila od 100 mg u 14 bolesnika s teškom bolesti koronarnih arterija ( &gt; 70% stenoza barem jedne koronarne arterije), srednji sistolički i dijastolički krvni tlak u mirovanju je snižen za 7%, odnosno 6% u usporedbi s početnom vrijednosti.
In a study of the hemodynamic effects of a single oral 100 mg dose of sildenafil in 14 patients with severe coronary artery disease (CAD) ( &gt; 70% stenosis of at least one coronary artery), the mean resting systolic and diastolic blood pressures decreased by 7% and 6% respectively compared to baseline.
U ispitivanju hemodinamičkih učinaka jednokratne oralne doze sildenafila od 100 mg u 14 bolesnika s teškom bolesti koronarnih arterija ( &gt; 70% stenoza barem jedne koronarne arterije), srednji sistolički i dijastolički krvni tlak u mirovanju je snižen za 7%, odnosno 6% u usporedbi s početnom vrijednosti.
In a three-month oral nonclinical study in the rat species with fenofibric acid, the active metabolite of fenofibrate, toxicity for the skeletal muscles (particularly those rich in type I -slow oxidative- myofibres) and cardiac degeneration, anemia and decreased body weight were seen at exposure levels ≥50- fold the human exposure for the skeletal toxicity and &gt; 15 fold for the cardiomyotoxicity.
U tromjesečnom peroralnom nekliničkom ispitivanju u štakora provedenom s fenofibričnom kiselinom, aktivnim metabolitom fenofibrata, zapažene su toksičnost skeletne muskulature (naročito one bogate nisko-oksidativnim mišićnim vlaknima tipa I) i degeneracija srca, anemija i smanjena tjelesna težina pri razinama izlaganja ≥50 puta ljudske izloženosti za skeletnu toksičnost i &gt; 15 puta za kardiomiotoksičnost.
In about 10-15% of patients treated with ulipristal acetate the endometrium may thicken ( &gt; 16 mm) during the first 3-month treatment course.
Kod približno 10-15% bolesnica liječenih ulipristalacetatom endometrij se može zadebljati ( &gt; 16 mm) tijekom prvog 3-mjesečnog ciklusa liječenja.
In addition patient or caregiver must comply with the injection technique as well as with the dosing regimen to ensure anti-HBs trough serum levels &gt; 100 IU/l after extended periods between level controls.
Osim toga, bolesnik ili njegovatelj moraju se pridržavati tehnike injiciranja kao i režima doziranja kako bi se nakon duljih razdoblja između kontrola razine osigurale najniže razine anti-HBs-a u serumu &gt; 100 IU/l.
In addition, 25 mg alogliptin alone and in combination with 30 mg pioglitazone produced statistically significant (p &lt; 0.001) reductions in total triglycerides at Week 16 as measured by postprandial incremental AUC(0-8) change from baseline compared to placebo.
Dodatno, 25 mg alogliptina, samog ili u kombinaciji s 30 mg pioglitazona, dovelo je u 16. tjednu u odnosu na placebo do statistički značajnih (p &lt; 0,001) sniženja ukupnih triglicerida izmjerenih kao postprandijalna inkrementalna promjena AUC(0-8) od početne vrijednosti.
In addition, 25 mg alogliptin alone and in combination with 30 mg pioglitazone produced statistically significant (p &lt; 0.001) reductions in total triglycerides at Week 16 as measured by postprandial incremental AUC(0-8) change from baseline compared to placebo.
Dodatno, 25 mg alogliptina, samog ili u kombinaciji s 30 mg pioglitazona, dovelo je u 16. tjednu u odnosu na placebo do statistički značajnog (p &lt; 0,001) sniženja ukupnih triglicerida izmjerenih kao postprandijalna inkrementalna promjena AUC(0-8) od početne vrijednosti.
In addition, 25 mg alogliptin alone and in combination with 30 mg pioglitazone produced statistically significant (p &lt; 0.001) reductions in total triglycerides at Week 16 as measured by postprandial incremental AUC(0-8) change from baseline compared to placebo.
Dodatno, 25 mg alogliptina, samog ili u kombinaciji s 30 mg pioglitazona, dovelo je u 16. tjednu u usporedbi s placebom do statistički značajnih (p &lt; 0,001) sniženja ukupnih triglicerida izmjerenih kao postprandijalna inkrementalna promjena AUC(0-8) od početne vrijednosti.
In addition, Abraxane is not recommended in patients with metastatic adenocarcinoma of the pancreas that have moderate to severe hepatic impairment (total bilirubin &gt; 1.5 x ULN and AST ≤ 10 x ULN) (see section 5.2).
Nadalje, Abraxane se ne preporučuje u bolesnika s metastatskim adenokarcinomom pankreasa i umjerenim do teškim oštećenjem jetrene funkcije (ukupni bilirubin &gt; 1,5 x GGN i AST ≤ 10 x GGN) (vidjeti dio 5.2).
In addition, caution should be exercised in treating patients with increased cardiac risk, e.g. hypertension, documented coronary artery disease, CHF, LVEF of &lt; 55%, older age.
Osim toga, neophodan je oprez pri liječenju bolesnika u kojih postoji povećan srčani rizik, npr. hipertenzija, dokumentirana bolest koronarnih arterija, kongestivno zatajenje srca, ejekcijska frakcija lijeve klijetke (LVEF) &lt; 55%, starija dob.
In addition, for the overall population, Mirvaso demonstrated statistical superiority (p &lt; 0.001) over vehicle gel with respect to rapid initial onset of a clinically meaningful effect (1-Grade Composite Success for CEA and PSA) after the first application at 30 minutes on Day 1(secondary endpoint 27.9% vs.
Osim toga, za ukupnu populaciju, Mirvaso se pokazao statistički superiorniji (p &lt; 0,001) od podloge gela u pogledu brzog nastupanja klinički značajnog učinka (kompozitna 1-stupanjska uspješnost za CEA i PSA) nakon prve primjene u 30 minuta na
In addition, in the first study involving 25 patients, Replagal effected a significant reduction in cardiac mass after 12 to 18 months of maintenance therapy (p &lt; 0.001).
Osim toga, u prvom ispitivanju koje je uključivalo 25 bolesnika utvrđena je značajna redukcija srčane mase nakon 12 - 18 mjeseci terapije održavanja Replagalom (p &lt; 0,001).
In addition, mean change from baseline in fasting plasma glucose at Week 52 for 25 mg alogliptin plus 30 mg pioglitazone and metformin was significantly greater than that for 45 mg pioglitazone and metformin (p &lt; 0.001).
Dodatno, srednja vrijednost promjene od početne vrijednosti glukoze u plazmi natašte bila je u 52. tjednu značajno veća s 25 mg alogliptina i 30 mg pioglitazona i metforminom nego za 45 mg pioglitazona s metforminom (p &lt; 0,001).
In addition, mean change from baseline in fasting plasma glucose at Week 52 for 25 mg alogliptin plus 30 mg pioglitazone and metformin was significantly greater than that for 45 mg pioglitazone and metformin (p &lt; 0.001).
Dodatno, srednja vrijednost promjene od početne vrijednosti glukoze u plazmi natašte bila je u 52. tjednu značajno veća za 25 mg alogliptina s 30 mg pioglitazona i metforminom nego za 45 mg pioglitazona s metforminom (p &lt; 0,001).
In addition, mean change from baseline in FPG at Week 52 for 25 mg alogliptin plus 30 mg pioglitazone and metformin was significantly greater than that for 45 mg pioglitazone and metformin (p &lt; 0.001).
Dodatno, srednja vrijednost promjene od početne vrijednosti glukoze u plazmi natašte bila je u 52. tjednu značajno veća za 25 mg alogliptina s 30 mg pioglitazona i metforminom nego za 45 mg pioglitazona s metforminom (p &lt; 0,001).
In addition, osteoarthritis and pain in extremity were reported with frequency uncommon ( &gt; 0.5 % higher among sitagliptin users than that in the control group).
Dodatno, prijavljeni su i osteoartritis te bol u ekstremitetima, uz kategoriju učestalosti manje često (učestalost u bolesnika liječenih sitagliptinom bila je &gt; 0,5% veća nego u kontrolnoj skupini).
In addition, the corresponding frequency category for each ADR is based on the CIOMS III convention and is defined as: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000); not known (cannot be estimated from available data).
Nadalje, odgovarajuće kategorije učestalosti svih nuspojava definirane su na temelju CIOMS III konvencije: vrlo često (≥1/10); često (≥1/100 do &lt; 1/10); manje često (≥1/1000 do &lt; 1/100); rijetko (≥1/10 000 to &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000); nepoznato (ne može se procijeniti iz dostupnih podataka).
In addition, the corresponding frequency category for each ADR is based on the following convention: very common (≥ 1/10); common (≥ 1/100 to &lt; 1/10); uncommon (≥ 1/1,000 to &lt; 1/100); rare (≥ 1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000).
Osim toga, odgovarajuća kategorija učestalosti za svaku nuspojavu definirana je na sljedeći način: vrlo često (≥ 1/10); često (≥ 1/100 i &lt; 1/10); manje često (≥ 1/1000 i &lt; 1/100); rijetko (≥ 1/10 000 i &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000).
In addition, the corresponding frequency category for each adverse drug reaction is based on the following convention (CIOMS III): very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000); not known (cannot be estimated from the available data).
Uz to, odgovarajuća kategorija učestalosti za svaku nuspojavu temelji se na sljedećoj konvenciji (CIOMS III): vrlo često (≥ 1/10); često (≥ 1/100 i &lt; 1/10); manje često (≥ 1/1000 i &lt; 1/100); rijetko (≥ 1/10 000 i &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000); nepoznato (ne može se procijeniti iz dostupnih podataka).
In addition, the corresponding frequency category for each adverse drug reaction is based on the following convention: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000).
Osim toga, odgovarajuća kategorija učestalosti za svaku nuspojavu na lijek određena je na sljedeći način: vrlo često (≥1/10); često (≥1/100 i &lt; 1/10); manje često (≥1/1000 i &lt; 1/100); rijetko (≥1/10 000 i &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000).
In addition, the corresponding frequency category for each adverse drug reaction is based on the following convention: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000).
Uz to, odgovarajuća kategorija učestalosti za svaku nuspojavu temelji se na sljedećoj konvenciji: vrlo često (≥1/10); često (≥1/100 i &lt; 1/10); manje često (≥1/1000 i &lt; 1/100); rijetko (≥1/10 000 i &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000).
In addition, the corresponding frequency category for each adverse reaction is based on the following convention: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000); not known (cannot be estimated from the available data).
Osim toga, odgovarajuća kategorija učestalosti za svaku nuspojavu određuje se na sljedeći način: vrlo često (≥ 1/10), često (≥ 1/100 i &lt; 1/10), manje često (≥ 1/1000 i &lt; 1/100), rijetko (≥ 1/10 000 i &lt; 1/1000), vrlo rijetko ( &lt; 1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka).
In addition, the corresponding frequency category for each adverse reaction is based on the following convention: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000); not known (cannot be estimated from the available data).
Osim toga, odgovarajuća kategorija učestalosti za svaku nuspojavu temelji se na sljedećem načelu: vrlo često (≥1/10); često (≥1/100 i &lt; 1/10); manje često (≥1/1000 i &lt; 1/100); rijetko (≥1/10 000 i &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000); nepoznato (ne može se procijeniti iz dostupnih podataka).
In addition, the corresponding frequency category for each adverse reaction is based on the following convention: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000, &lt; 1/1,000); very rare ( &lt; 1/10,000); not known (cannot be estimated from the available data).
Osim toga, odgovarajuća kategorija učestalosti za svaku nuspojavu temelji se na sljedećem načelu: vrlo često (≥1/10); često (≥1/100 i &lt; 1/10); manje često (≥1/1000 i &lt; 1/100); rijetko (≥1/10 000 i &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000); nepoznato (ne može se procijeniti iz dostupnih podataka).
In addition, the corresponding frequency category is provided using the following convention: Very common ( 1/10); Common ( 1/100 to &lt; 1/10); Uncommon ( 1/1,000 to &lt; 1/100); Rare ( 1/10,000 to &lt; 1/1,000); Very rare ( &lt; 1/10,000).
Uz to, za svaku je nuspojavu navedena i odgovarajuća kategorija učestalosti prema sljedećem načelu: vrlo često ( 1/10); često ( 1/100 do &lt; 1/10); manje često ( 1/1000 do &lt; 1/100); rijetko ( 1/10 000 do &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000).
In addition, the corresponding frequency category using the following convention (CIOMS III) is also provided for each adverse drug reaction: very common (≥1/10); common (≥1/100 to &lt; 1/10); uncommon (≥1/1,000 to &lt; 1/100); rare (≥1/10,000 to &lt; 1/1,000); very rare ( &lt; 1/10,000); not known: frequency cannot be estimated from the available data.
Uz to, za svaku je nuspojavu navedena i odgovarajuća kategorija učestalosti prema sljedećem načelu (CIOMS III): vrlo često (≥1/10); često (≥1/100 i &lt; 1/10); manje često (≥1/1000 i &lt; 1/100); rijetko (≥1/10 000 i &lt; 1/1000); vrlo rijetko ( &lt; 1/10 000); nepoznato: učestalost se ne može procijeniti iz dostupnih podataka.
In addition, there have been few reports ( &lt; 1%), some fatal, of subjects presenting with seizures and radiological evidence of reversible posterior leukoencephalopathy syndrome (RPLS).
Osim toga, postoje malobrojna izvješća ( &lt; 1%) neka i fatalna, o ispitanicima kod kojih su se javili napadaji s radiološki potvrđenim sindromom reverzibilne posteriorne leukoencefalopatije (engl. reversible posterior leukoencephalopathy syndrome, RPLS).
In adolescents weighing &lt; 51 kg, a 23% higher exposure was observed than in adolescents weighing ≥ 51 kg.
U adolescenata težine &lt; 51 kg, bila je zapažena 23% veća izloženost nego u adolescenata težine ≥ 51 kg.
in adult and paediatric patients with beta thalassaemia major with iron overload due to infrequent blood transfusions ( &lt; 7 ml/kg/month of packed red blood cells) aged 2 years and older, in adult and paediatric patients with other anaemias aged 2 years and older.
odrasli i pedijatrijski bolesnici s beta-talasemijom major i preopterećenjem željezom zbog neučestalih transfuzija krvi ( &lt; 7 ml/kg/mjesec koncentrata eritrocita) u dobi od 2 godine i stariji, odrasli i pedijatrijski bolesnici s drugim vrstama anemija u dobi od 2 godine i stariji.
In adults treated with abacavir in combination with lamivudine and zidovudine the proportion of patients with undetectable viral load ( &lt; 400 copies/ml) was approximately 70% (intention to treat analysis at 48 weeks) with corresponding rise in CD4 cells.
U odraslih bolesnika liječenih abakavirom u kombinaciji s lamivudinom i zidovudinom, udio bolesnika s virusnim opterećenjem ispod razine detekcije ( &lt; 400 kopija/ml) bio je oko 70% (analiza bolesnika s namjerom liječenja nakon 48 tjedana), uz odgovarajući porast broja CD4 stanica.